|
1
|
Martini N, Bains MS, Burt ME, et al:
Incidence of local recurrence and second primary tumors in resected
stage I lung cancer. J Thorac Cardiovasc Surg. 109:120–129. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
al-Kattan K, Sepsas E, Fountain SW and
Townsend ER: Disease recurrence after resection for stage I lung
cancer. Eur J Cardiothorac Surg. 12:380–384. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yoshino I, Yohena T, Kitajima M, et al:
Survival of non-small cell lung cancer patients with postoperative
recurrence at distant organs. Ann Thorac Cardiovasc Surg.
7:204–209. 2001.
|
|
4
|
Martin J, Ginsberg RJ, Venkatraman ES, et
al: Long-term results of combined-modality therapy in resectable
non-small-cell lung cancer. J Clin Oncol. 20:1989–1995. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Williams BA, Sugimura H, Endo C, et al:
Predicting post-recurrence survival among completely resected
nonsmall-cell lung cancer patients. Ann Thorac Surg. 81:1021–1027.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sugimura H, Nichols FC, Yang P, et al:
Survival after recurrent non-small-cell lung cancer after complete
pulmonary resection. Ann Thorac Surg. 83:409–418. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hung JJ, Hsu WH, Hsieh CC, et al:
Post-recurrence survival in completely resected stage I non-small
cell lung cancer with local recurrence. Thorax. 64:192–196. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shimada Y, Saji H, Yoshida K, et al:
Prognostic factors and the significance of treatment after
recurrence in completely resected stage I non-small cell lung
cancer. Chest. 143:1626–1634. 2013.PubMed/NCBI
|
|
9
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
11
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paz-Ares L, de Marinis F, Dediu M, et al:
Maintenance therapy with pemetrexed plus best supportive care
versus placebo plus best supportive care after induction therapy
with pemetrexed plus cisplatin for advanced non-squamous
non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3,
randomised controlled trial. Lancet Oncol. 13:247–255. 2012.
|
|
13
|
Reck M, von Pawel J, Zatloukal P, et al:
Overall survival with cisplatin-gemcitabine and bevacizumab or
placebo as first-line therapy for nonsquamous non-small-cell lung:
results from a randomised phase III trial (AVAiL). Ann Oncol.
21:1804–1809. 2010. View Article : Google Scholar
|
|
14
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sasaki H, Endo K, Mizuno K, et al: EGFR
mutation status and prognosis for gefitinib treatment in Japanese
lung cancer. Lung Cancer. 51:135–136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fukuoka M, Wu YL, Thongprasert S, et al:
Biomarker analyses and first overall survival results from a phase
III, randomized, open-label, first-line study of gefitinib versus
carboplatin/paclitaxel in clinically selected patients with
advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol.
29:2866–2874. 2011. View Article : Google Scholar
|
|
19
|
The Japan Lung Cancer Society. The General
Rule for Clinical and Pathological Record of Lung Cancer. 7th
edition. Kanehara Shuppan; Tokyo, Japan: pp. 1–234. 2010
|
|
20
|
Sasaki H, Endo K, Konishi A, et al: EGFR
mutation status in Japanese lung cancer patients: genotyping
analysis using LightCycler. Clin Cancer Res. 11:2924–2929. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sasaki H, Shimizu S, Endo K, et al: EGFR
and erbB2 mutation status in Japanese lung cancer patients. Int J
Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ichinose Y, Yano T, Yokoyama H, et al:
Postrecurrent survival of patients with non-small-cell lung cancer
undergoing a complete resection. J Thorac Cardiovasc Surg.
108:158–161. 1994.PubMed/NCBI
|
|
23
|
Walsh GL, O’Connor M, Willis KM, et al: Is
follow-up of lung cancer patients after resection medically
indicated and cost-effective? Ann Thorac Surg. 60:1563–1572. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ichinose Y, Kato H, Koike T, et al:
Overall survival and local recurrence of 406 completely resected
stage IIIa-N2 non-small cell lung cancer patients: questionnaire
survey of the Japan Clinical Oncology Group to plan for clinical
trials. Lung Cancer. 34:29–36. 2001. View Article : Google Scholar
|
|
25
|
Mitsudomi T, Nishioka K, Maruyama R, et
al: Kinetic analysis of recurrence and survival after potentially
curative resection of nonsmall cell lung cancer. J Surg Oncol.
63:159–165. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yano T, Hara N, Ichinose Y, et al: Local
recurrence after complete resection for non-small-cell carcinoma of
the lung. Significance of local control by radition treatment. J
Thorac Cardiovasc Surg. 107:8–12. 1994.
|
|
27
|
Emami B, Graham MV, Deedy M, Shapiro S and
Kucik N: Radiation therapy for intrathoracic recurrence of
non-small cell lung cancer. Am J Clin Oncol. 20:46–50. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sequist LV, Joshi VA, Jänne PA, et al:
Response to treatment and survival of patients with non-small cell
lung cancer undergoing somatic EGFR mutation testing. Oncologist.
12:90–98. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang CH, Yu CJ, Shih JY, et al: Specific
EGFR mutations predict treatment outcome of stage IIIB/IV patients
with chemotherapy-naive non-small-cell lung cancer receiving
first-line gefitinib monotherapy. J Clin Oncol. 26:2745–2753. 2008.
View Article : Google Scholar
|
|
30
|
Kosaka T, Yatabe Y, Endo H, et al:
Analysis of epidermal growth factor receptor gene mutation in
patients with non-small cell lung cancer and acquired resistance to
gefitinib. Clin Cancer Res. 12:5764–5769. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar
|
